Strategic Review of Essa Pharma: Potential 27% Upside Amidst Halted Trials and Strong Shareholder Alignment
Essa Pharma (EPIX) halted pipeline development, launched a strategic review, with NAV/liquidation value estimated at $2.18/share.
131 Views
SSI Weekly: Galaxy Gaming Acquisition and Other Portfolio Updates
Galaxy Gaming is being acquired by Evolution AB for $3.20/share, with a 17% spread and minimal regulatory hurdles. Other updates follow.
137 Views
Key Updates on EPIX, HLVX, PRKR, BOOM, VZIO, WOW, AVAP:L, LOGC, LFCR, DK
Essa Pharma (EPIX) halted pipeline development, launched strategic review, offering 21% upside to NAV/liquidation value by mid-2025.
140 Views